80岁及以上房颤患者利伐沙班与维生素K拮抗剂出血风险比较
本研究为法国33家老年中心的前瞻性序贯观察队列,纳入≥80岁非瓣膜性房颤患者,分别新启用VKA(908例)或利伐沙班(995例),随访12个月。经倾向评分匹配和Cox模型分析,利伐沙班大出血风险显著低于VKA,主要驱动于脑出血风险降低。
要点
- ≥80岁非瓣膜性房颤患者中,利伐沙班大出血风险低于VKA。
- 脑出血发生风险在利伐沙班组更低,为大出血风险降低的主要驱动因素。
- 该结论来自观察性队列,需结合患者个体情况谨慎应用于临床。
核心结论
- 在≥80岁非瓣膜性房颤患者中,利伐沙班出血风险低于VKA,主要驱动于脑出血风险降低。
研究设计与样本
- 前瞻性序贯观察队列研究,数据来自33家老年中心。
- 样本包括2011年9月至2014年9月新启用VKA的908例患者和2014年9月至2017年9月新启用利伐沙班的995例患者,随访至12个月。
- 采用倾向评分匹配和Cox模型比较两组结局。
主要发现
- 利伐沙班组大出血风险为7.4/100患者年,VKA组为14.6/100患者年,多因素校正后HR 0.66(95%CI 0.43-0.99),倾向评分匹配样本HR 0.53(95%CI 0.33-0.85)。
- 利伐沙班组脑出血发生率为1.3/100患者年,VKA组为4.0/100患者年,校正HR 0.59(95%CI 0.24-1.44),倾向评分匹配样本HR 0.26(95%CI 0.09-0.80)。
- 大出血风险降低主要由脑出血风险降低驱动。
临床怎么用
- 对于≥80岁非瓣膜性房颤患者,利伐沙班可作为VKA的替代选择以降低出血风险,尤其脑出血风险。
局限性
- 研究为观察性设计,可能存在残余混杂。
- 样本来自法国老年中心,外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Direct oral anticoagulants have been evaluated in the general population, but proper evidence for their safe use in the geriatric population is still missing. We compared the bleeding risk of a direct oral anticoagulant (rivaroxaban) and vitamin K antagonists (VKAs) among French geriatric patients with non-valvular atrial fibrillation (AF) aged ≥80 years. METHODS: We performed a sequential observational prospective cohort study, using data from 33 geriatric centres. The sample comprised 908 patients newly initiated on VKAs between September 2011 and September 2014 and 995 patients newly initiated on rivaroxaban between September 2014 and September 2017. Patients were followed up for up to 12 months. One-year risks of major, intracerebral, gastrointestinal bleedings, ischaemic stroke and all-cause mortality were compared between rivaroxaban-treated and VKA-treated patients with propensity score matching and Cox models. RESULTS: Major bleeding risk was significantly lower in rivaroxaban-treated patients (7.4/100 patient-years) compared with VKA-treated patients (14.6/100 patient-years) after multivariate adjustment (HR 0.66; 95% CI 0.43 to 0.99) and in the propensity score-matched sample (HR 0.53; 95% CI 0.33 to 0.85). Intracerebral bleeding occurred less frequently in rivaroxaban-treated patients (1.3/100 patient-years) than in VKA-treated patients (4.0/100 patient-years), adjusted HR 0.59 (95% CI 0.24 to 1.44) and in the propensity score-matched sample HR 0.26 (95% CI 0.09 to 0.80). Major lower bleeding risk was largely driven by lower risk of intracerebral bleeding. CONCLUSIONS: Our study findings indicate that bleeding risk, largely driven by lower risk of intracerebral bleeding, is lower with rivaroxaban than with VKA in stroke prevention in patients ≥80 years old with non-valvular AF.
引用
- Hanon O, Vidal JS, Pisica-Donose G, et al. Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation. Heart. 2020. PMID: 33262185. doi:10.1136/heartjnl-2020-317923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。